| Code | CSB-RA005165MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to labetuzumab, targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), also known as CD66e or CEA. CEACAM5 is a glycosylphosphatidylinositol-anchored cell surface glycoprotein that functions in cell adhesion, intracellular signaling, and immune modulation. It is normally expressed at low levels on the apical surface of gastrointestinal epithelial cells but becomes significantly overexpressed and aberrantly distributed in various malignancies, particularly colorectal, pancreatic, gastric, and non-small cell lung cancers. Elevated CEACAM5 expression correlates with tumor progression, metastasis, and poor prognosis, making it a valuable tumor-associated antigen.
Labetuzumab is a humanized IgG1 monoclonal antibody that specifically recognizes CEACAM5 and has been extensively studied in oncology research and clinical trials for targeted cancer therapy. This biosimilar antibody provides researchers with a reliable tool for investigating CEACAM5 biology, tumor immunology, cancer cell signaling pathways, and the development of diagnostic and therapeutic strategies targeting CEACAM5-expressing malignancies.
There are currently no reviews for this product.